Growing advancements in technology to drive the flow cytometry in oncology market in the forecast period, 2023-2027.
According to TechSci Research report, “Flow Cytometry in Oncology Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027”, the global flow cytometry in oncology market is anticipated to grow at a significant rate in the forecast period, 2023-2027. The growing occurrences of cancer and hematological malignancies, the increasing adoption of flow cytometry techniques in research and academia, and technological evolution in the field of flow cytometry are the primary factors driving the demand for the global flow cytometry in oncology market. The rise in R&D activities, increasing number of clinical trials along with the adoption of flow cytometry for various research applications, growing favorable government funding, surge in the number of cases suffering from cancer, and rising healthcare expenditure, are expected to influence the market demand. Also, the growing adoption of inorganic growth strategies, and increasing fund infusions for hematological malignancies are also a key factor for increasing the growth of the flow cytometry in oncology market, globally.
However, high cost of the equipment, and lack of awareness about the potential benefits of flow cytometry techniques may hamper the growth of the global flow cytometry in oncology market.
Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on “Global Flow Cytometry in Oncology Market“
The global flow cytometry in oncology market is segmented into component, technology, indication, application, end user, and company.
Based on component, the market is divided into assays & kits, instruments, reagents & consumables, and software. The instruments segment is expected to hold the largest market share. This is attributed to the introduction of novel cytometers by key players, new advancements in technology, and rising awareness of innovative technologies.
Based on technology, the market is divided into cell based and bead based. The cell-based segment is anticipated to grow during the forecast period. This is attributed to the rising awareness related to the associated benefits of cell-based assays, simultaneous analysis of multiple samples, lesser time consumption and advancements in technologies of cell-based assays.
Based on indication, the market is divided into hematological malignancies and solid tumors. The hematological malignancies segment is anticipated to grow during the forecast period. This is attributed to the growing incidents of leukemia, and rising demand for early detection of the cancer.
Based on application, the market is divided into translational research and clinical applications. The translational research segment is anticipated to grow during the forecast period. This is attributed to the increasing R&D activities related to cancer, and growing R&D investments in the pharmaceutical and biotechnology industry.
Based on end user, the market is divided into hospitals & clinics, diagnostic laboratories, academic & research institutions, and others. The hospitals & clinics segment is anticipated to grow during the forecast period. This is attributed to the increasing prevalence of cancer, growing healthcare infrastructure, surge in number of cases suffering from cancer, and the increasing number of multispecialty hospitals.
Major companies operating in global flow cytometry in oncology market are:
- Agilent Technologies, Inc.
- Apogee Flow Systems Ltd.
- Becton, Dickinson and Company
- bioAffinity Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- Cytognos, S.L.
- Danaher Corporation
- Miltenyi Biotec B.V. & Co. KG
- Laboratory Corporation of America Holdings
Customers can also request for 10% free customization on this report.
“North America region dominates the market in 2021 and is expected to maintain its dominance in the coming years due to well-established healthcare infrastructure and rise in adoption of technologically advanced flow cytometry instruments. The extensive research activities by research universities and pharmaceutical industries, existing advanced healthcare facilities, increasing burden of cancer, large patient pool, increase in healthcare expenditure and high infusion of funding from the government organizations for conducting cancer research in the healthcare sector in the region are expected to propel the global flow cytometry in oncology market growth till 2027” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Flow Cytometry in Oncology Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027, Segmented By Component (Assays & Kits, Instruments, Reagents & Consumables, Software), By Technology (Cell Based v/s Bead Based), By Indication (Hematological Malignancies v/s Solid Tumors), By Application (Translational Research v/s Clinical Applications), By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others), By company and By Region”, has evaluated the future growth potential of global flow cytometry in oncology market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global flow cytometry in oncology market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com
